News

Treatments options for various histologies of leukemia are expanding with FDA approvals for drugs such as the combination of ivosidenib/azacitidine and the CAR T-cell therapy brexucabtagene autoleucel.

Patients with hormone-sensitive prostate cancer who received darolutamide in combination with docetaxel experienced superior overall survival and time-to-pain progression benefit.

The biologics license application for omidubicel has been granted priority review and will be assessed as a potential treatment for patients with blood cancer who require allogeneic hematopoietic stem cell transplant.

The FDA has scheduled 3 sessions for the Oncologic Drugs Advisory Committee to review updates on the new drug application for poziotinib tablets and data for the continued approval of indications for melphalan flufenamide and duvelisib.

The FDA has approved the first targeted therapy for patients with HER2-low metastatic breast cancer.

Medical providers should strive to make all patients feel welcome and safe.

Sherry Adkins, MSN, ANP-C, discusses the significance of incorporating CAR T-cell therapy regimens, such as lisocabtagene autoleucel, into earlier lines of treatment for patients with relapsed/refractory large B-cell lymphoma.

At the 6th Annual SONO meeting, Beth Sandy, MSN, CRNP, reviewed available treatment options for patients with identified driver mutations in non–small cell lung cancer.

A joint statement from the American Society of Clinical Oncology and the Association of Community Cancer Centers outlines steps to reduce gaps in care for underserved communities.

Paula Anastasia, RN, MN, AOCN, discusses the value of germline testing and the role of maintenance PARP inhibitor therapy in optimized ovarian cancer treatment.

Kelley A. Rone, DNP, RN, ADNP-c, highlights the pivotal trials assessing the role of immunotherapy in gastrointestinal cancer and what the findings may mean for oncology nurses.

Faith Mutale, CRNP, discusses the paradigm shift needed in oncology to address clinical trial enrollment hesitancy among African American patients with lung cancer.

Sarah Donahue, MPH, NP, AOCNP, explains the trial design of the pivotal DESTINY-Breast04 trial and discusses how the promising performance of trastuzumab deruxtecan might impact patients with unresectable or metastatic HER2-low breast cancer.

New data demonstrated the safety and efficacy of amivantamab-vmjw plus lazertinib and platinum-based chemotherapy in patients with relapsed or refractory, EGFR-mutant non–small cell lung cancer.

In the modern era, the number of patients with diffuse large B-cell lymphoma who will derive benefit from autologous stem cell transplantation is small, according to Jeremy S. Abramson, MD, MMSc.

Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from July 2022.

Chinese patients with newly diagnosed advanced ovarian cancer whose disease responsed to first-line chemotherapy experienced significantly improved progression-free survival with niraparib.

Gabriella Magarelli, MSN, ACNP-BC, AOCNP, reflects on lessons learned caring for patients with cancer and COVID-19.

An analysis of patient-reported outcomes from the phase 3, INTRIGUE trial (NCT03673501) showed that ripretinib had a more tolerable safety profile than sunitinib in treating patients with advanced GIST tumors.

In early-stage cancers, ctDNA has a role in screening, neoadjuvant monitoring, identification of molecular residual disease (MRD), molecular relapse monitoring, and early assessment of treatment response.

Based on data from the DESTINY-Breast04 trial, the FDA has granted a priority review designation for the supplemental biologics license application for fam-trastuzumab deruxtecan-nxki.

Lidia Schapira, MD, FASCO, discusses the importance of rigorous baseline measurement in improving the assessment and management of distressful cancer symptoms.

Gretchen McNally, PhD, ANP-BC, AOCNP, discusses the rationale behind a pilot study which will assess patient reported outcomes for patients with lymphoma who develop chemotherapy-induced peripheral lymphoma.

An expert with the Washington University School of Medicine in St Louis outlines the benefit of rituximab, and other maintenance therapies, for patients with mantel cell lymphoma who are in remission.

Phase 3 findings from the POLARIX trial showed that the addition of platuzumab vedotin to rituximab, cyclophosphamide, doxorubicin, and prednisone resulted in a 27% reduction in risk of disease progression, relapse, or death for patients with newly diagnosed diffuse large B-cell lymphoma.

A quality time without symptoms of toxicities analysis of the pivotal ZUMA-7 trial found that patients with relapsed or refractory large B-cell lymphoma experienced longer time without toxicity with axicabtagene ciloleucel than with standard of care.

Mosunetuzumab, a CD20 and CD3 T-cell engaging bispecific antibody, received a priority review designation from the FDA for the treatment of patients with relapsed/refractory follicular lymphoma following at least 2 prior systemic therapies.

A combined analysis of 3 real-world studies assessing the use of ixazomib/lenalidomide/dexamethasone (IRd) in patients with relapsed or refractory multiple myeloma found the patient outcomes to be consistent with original phase 3 findings.

Patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, achieved superior progression-free survival with zanubrutinib vs a combination of bendamustine plus rituximab.